stockrow
Saturday 7 November 2026
Export INBX’s income statement to Excel — free account
Inhibrx Biosciences, Inc.
INBX Healthcare Biotechnology
Inhibrx Biosciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.3 million, up 550.0% from fiscal 2024.
- Revenue
- +992.4%
- EPS
- −26.5%
- Free cash flow
- +0.12%
- Total debt
- +77.6%
Quarter to June 2026, against a year earlier
85.46
5.18
+6.45%
Follow INBX
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
4.76 | 6.10 | 3.68 | 4.28 | |
Current Ratio |
5.07 | 6.46 | 3.93 | 4.49 | |
Net Debt/EBITDA |
(1.36) | (0.44) | 0.78 | 1.60 | |
Debt/Assets |
114.31% | 95.12% | 68.65% | 56.30% | |
Debt/Equity |
(3.33) | (8.32) | 12.58 | 2.71 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.82 | 1.14 | 0.92 | 0.96 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | (0.01) | |
Interest Coverage |
(5.65) | (8.81) | (9.71) | (10.63) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.91) | (2.44) | (1.94) | (2.19) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.91) | (2.44) | (1.94) | (2.19) | |
Cash per Share |
8.51 | 10.37 | 8.02 | 9.89 | |
Shareholders Equity per Share |
(3.38) | (1.35) | 0.52 | 2.38 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(3.38) | (1.35) | 0.52 | 2.38 | |
Free Cash Flow |
(29.92) | (38.03) | (30.12) | (33.83) | |
Working Capital |
114.15 | 144.83 | 99.03 | 125.44 | |
Capital Expenditures |
— | — | 0.00 | (0.01) | |
Net Current Asset Value |
(64.99) | (33.66) | (5.65) | 20.78 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
— | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.55 | 0.20 | 0.30 | 0.98 | |
Average Payables |
9.05 | 8.83 | 7.59 | 9.57 | |
Average Assets |
183.17 | 213.30 | 163.62 | 200.02 | |
Average Common Equity |
7.79 | 36.70 | 70.79 | 107.65 |
Columns are period end dates · fundamentals updated 26 Oct 2026